Back to User profile » Professor Alain Vergnenègre
Papers published by Professor Alain Vergnenègre:
Potential Antiangiogenic Treatment Eligibility of Patients with Squamous Non-Small–Cell Lung Cancer: EPISQUAMAB Study (GFPC 2015-01)
Vergnenègre A, Basse V, Le Garff G, Bylicki O, Dubos-Arvis C, Comet B, Marcq M, Le Treut J, Auliac JB, Madroszyk A, Fraboulet G, Crequit J, Thomas P, Paleiron N, Monnet I
Cancer Management and Research 2019, 11:10821-10826
Published Date: 27 December 2019
Economic evaluation of first-line and maintenance treatments for advanced non-small cell lung cancer: a systematic review
Chouaïd C, Crequit P, Borget I, Vergnenegre A
ClinicoEconomics and Outcomes Research 2015, 7:9-15
Published Date: 15 December 2014
Update on the treatment of non-small-cell lung cancer: focus on the cost-effectiveness of new agents
Vergnenègre A, Borget I, Chouaid C
ClinicoEconomics and Outcomes Research 2013, 5:137-141
Published Date: 10 April 2013
Maintenance erlotinib in advanced nonsmall cell lung cancer: cost-effectiveness in EGFR wild-type across Europe
Walleser S, Ray J, Bischoff H, Vergnenègre A, Rosery H, Chouaid C, Heigener D, de Castro Carpeño J, Tiseo M, Walzer S
ClinicoEconomics and Outcomes Research 2012, 4:269-275
Published Date: 14 September 2012
Cross-market cost-effectiveness analysis of erlotinib as first-line maintenance treatment for patients with stable non-small cell lung cancer
Vergnenègre A, Ray JA, Chouaid C, Grossi F, Bischoff HG, Heigener DF, Walzer S
ClinicoEconomics and Outcomes Research 2012, 4:31-37
Published Date: 26 January 2012